Sacubitril/Valsartan Reduces Mortality More Than ACE Inhibitors in HFrEF

Sacubitril/Valsartan Reduces Mortality More Than ACE Inhibitors in HFrEF

Introduction

Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality worldwide. For decades, ACE inhibitors were the cornerstone of therapy because they reduce mortality and hospitalization. However, the development of angiotensin receptor–neprilysin inhibitors (ARNIs), particularly sacubitril/valsartan, has significantly improved outcomes. Large randomized trials have demonstrated that sacubitril/valsartan reduces mortality and heart-failure hospitalizations more effectively than ACE inhibitors, leading to major changes in heart-failure guidelines.

---

Mechanism of Action

Sacubitril/valsartan combines two pharmacologic mechanisms:

1. Sacubitril (Neprilysin inhibitor)

Inhibits neprilysin enzyme

Prevents breakdown of natriuretic peptides

Leads to:

Vasodilation

Natriuresis

Reduced cardiac remodeling

Decreased sympathetic activity

2. Valsartan (ARB)

Blocks angiotensin II type-1 receptors

Reduces vasoconstriction, sodium retention, and maladaptive RAAS activation

The dual mechanism simultaneously enhances beneficial natriuretic peptides while suppressing RAAS, producing stronger hemodynamic and neurohormonal effects than ACE inhibition alone.

---

Landmark Evidence: PARADIGM-HF Trial

The superiority of sacubitril/valsartan over ACE inhibitors was demonstrated in the PARADIGM-HF trial, one of the most important heart-failure trials.

Study design

> 8,400 patients with symptomatic HFrEF

Compared sacubitril/valsartan vs enalapril

Median follow-up: ~27 months

Key Outcomes

Outcome Reduction vs Enalapril

CV death or HF hospitalization 20% reduction

Cardiovascular mortality 20% reduction

HF hospitalization 21% reduction

All-cause mortality 16% reduction

Sacubitril/valsartan reduced all-cause mortality (19.0% vs 21.9%) compared with enalapril in the trial population. 

Overall, the drug significantly lowered both mortality and hospitalization compared with ACE inhibitors. 

The absolute mortality reduction was about 2.8% over ~27 months, translating to a number needed to treat (NNT) ≈ 36 to prevent one death. 

---

Real-World and Meta-analysis Data

Subsequent studies and meta-analyses confirmed these benefits.

Findings include:

15–23% reduction in all-cause mortality compared with ACEI/ARB therapy in observational studies. 

Significant reductions in cardiovascular mortality and HF hospitalization across multiple trials. 

Consistent improvement in outcomes in diverse populations with HFrEF. 

These results established ARNI therapy as superior RAAS-based therapy in systolic heart failure.

---

Impact on Clinical Guidelines

Because of the strong evidence, major cardiology guidelines recommend replacing ACE inhibitors with sacubitril/valsartan in appropriate patients.

ACC/AHA/HFSA Guidelines

Class I recommendation

Replace ACEI/ARB with ARNI in symptomatic HFrEF to reduce mortality and hospitalization. 

ESC Guidelines

ARNI recommended as part of foundational therapy for HFrEF along with:

Beta-blocker

Mineralocorticoid receptor antagonist

SGLT2 inhibitor. 

---

Practical Clinical Use

Sacubitril/valsartan is indicated in patients with:

HFrEF (LVEF ≤40%)

Symptomatic despite guideline-directed therapy

Previously tolerating ACEI or ARB

Important clinical points

ACE inhibitor must be stopped for 36 hours before starting ARNI to avoid angioedema. 

Monitor:

Blood pressure

Renal function

Potassium levels

---

Why Sacubitril/Valsartan Is Superior

ACE inhibitors target only the RAAS pathway, whereas sacubitril/valsartan:

1. Blocks RAAS (via valsartan)

2. Enhances natriuretic peptide system (via sacubitril)

This dual neurohormonal modulation improves:

Cardiac remodeling

Hemodynamics

Neurohormonal balance

As a result, patients experience lower mortality, fewer hospitalizations, and improved quality of life compared with ACE inhibitor therapy.

---

Conclusion

Sacubitril/valsartan represents a major therapeutic advancement in HFrEF. Compared with ACE inhibitors, it provides:

16% reduction in all-cause mortality

20% reduction in cardiovascular death

21% reduction in HF hospitalization

Because of these substantial benefits, modern heart-failure guidelines recommend ARNI therapy as a preferred alternative to ACE inhibitors in symptomatic HFrEF patients.

Sacubitril/valsartan has therefore become a cornerstone of guideline-directed medical therapy for systolic heart failure.